CliffBio
small molecule

ZUPLENZ

ONDANSETRON

Loss of exclusivityJuly 2030latest FDA-listed patent expiry
CompanyAquestive Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameZUPLENZ
Active ingredientONDANSETRON
Strength8MG
Dosage formFILM
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2010
Marketing statusDISCN

Listed patents

PatentExpiresType
9095577July 2030product
8580830November 2029product

More from Aquestive Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZUPLENZ patent cliff — loss of exclusivity July 2030 | CliffBio